KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Income from Continuing Operations (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Income from Continuing Operations readings, the most recent being 62597000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 315.28% to 62597000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 24331000.0, a 85.96% decrease, with the full-year FY2025 number at 22641000.0, up 56.25% from a year prior.
  • Income from Continuing Operations hit 62597000.0 in Q4 2025 for Esperion Therapeutics, up from 32010000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 62597000.0 in Q4 2025 to a low of 90949000.0 in Q1 2021.
  • Median Income from Continuing Operations over the past 5 years was 47636000.0 (2021), compared with a mean of 38067400.0.
  • The widest YoY moves for Income from Continuing Operations: up 315.28% in 2025, down 171.3% in 2025.
  • Esperion Therapeutics' Income from Continuing Operations stood at 69058000.0 in 2021, then rose by 17.69% to 56842000.0 in 2022, then decreased by 1.02% to 57424000.0 in 2023, then soared by 49.36% to 29077000.0 in 2024, then soared by 315.28% to 62597000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 62597000.0 (Q4 2025), 32010000.0 (Q3 2025), and 13391000.0 (Q2 2025) per Business Quant data.